SCHEMBL30989839

SCHEMBL30989839

CN(C(=O)c1cc(F)cnc1OC(F)F)C1COc2ccccc21

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TRPM8 Q7Z2W7 1/20 0.37
▸ PTGIR P43119 1/20 0.33
▸ GRM7 Q14831 3/20 0.33
▸ GPR6 P46095 1/20 0.32
▸ PSMB5 P28074 1/20 0.32
▸ HCRTR1 O43613 1/20 0.31
▸ HCRTR2 O43614 1/20 0.31
▸ PROKR1 Q8TCW9 1/20 0.31
▸ LTB4R Q15722 1/20 0.31
▸ LTB4R2 Q9NPC1 1/20 0.31
▸ FFAR1 O14842 1/20 0.30
▸ PTGDR2 Q9Y5Y4 1/20 0.30
▸ MAPK1 P28482 1/20 0.30
▸ SLC6A2 P23975 1/20 0.30
▸ SLC6A4 P31645 1/20 0.30
▸ KDM6B O15054 1/20 0.30
▸ KDM4C Q9H3R0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30989824 0.91 GPR6 (0.34) GPR6HCRTR1HCRTR2LTB4RLTB4R2
SCHEMBL30989815 0.90 TRPM8 (0.36) TRPM8HCRTR1HCRTR2MAPK1
SCHEMBL30989796 0.87 GPR6 (0.33) GPR6
SCHEMBL30989795 0.83 LTB4R (0.34) GPR6HCRTR1HCRTR2LTB4RLTB4R2
SCHEMBL30989838 0.80 GPR6 (0.39) GPR6HCRTR1HCRTR2KDM4C
SCHEMBL30989859 0.80 GPR6 (0.39) GPR6HCRTR1HCRTR2KDM4C
SCHEMBL30989805 0.80 GPR6 (0.39) GRM7GPR6HCRTR2
SCHEMBL30990026 0.80 MAPK1 (0.41) GPR6PTGDR2MAPK1KDM6BKDM4C
SCHEMBL30989831 0.80 MAPK1 (0.41) GPR6PTGDR2MAPK1KDM6BKDM4C
SCHEMBL30989814 0.77 MAPK1 (0.36) TRPM8HCRTR2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP claimed
WO-2024095003-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO claimed
EP-4612131-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024095003-A1 NICOTINAMIDE DERIVATIVES FOR USE IN TREATING DISORDERS ASSOCIATED WITH KCNK13 ACTIVITY Cerevance, Inc. (US) 2024-05-10 — — WO disclosed
Send feedback